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a b s t r a c t
A central challenge in cancer care is to ensure that therapeutic compounds reach their targets. One
approach is to use enzyme-responsive biomaterials, which reconﬁgure in response to endogenous en-
zymes that are overexpressed in diseased tissues, as potential site-speciﬁc anti-tumoral therapies. Here
we report peptide micelles that upon MMP-9 catalyzed hydrolysis reconﬁgure to form ﬁbrillar nano-
structures. These structures slowly release a doxorubicin payload at the site of action. Using both in vitro
and in vivo models, we demonstrate that the ﬁbrillar depots are formed at the sites of MMP-9 over-
expression giving rise to enhanced efﬁcacy of doxorubicin, resulting in inhibition of tumor growth in an
animal model.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cancer nanomedicines have the potential to lead to innovative
drug formulation strategies through the design of nanocarriers that
improve efﬁcacy and bioavailability, incorporate targeting oppor-
tunities and may lead to personalization as well as increased safety
compared to conventional medicines [1e3]. Development of suc-
cessful cancer nanomedicines has been hindered, however, due to
the lack of target speciﬁcity [4]. Nevertheless, some examples of
anti-cancer nanomedicines have reached the clinic. Currently
approved treatments include doxorubicin loaded PEGylated lipo-
some formulations (Doxil) for the treatment of ovarian cancer and
Karposi's sarcoma [4,5] and paclitaxel/albumin nanoparticles
(Abraxane) for the treatment of metastatic breast cancer [6,7].
These existing and other emerging [8] nanoformulations are
designed to enhance circulation of poorly soluble chemothera-
peutics. Other approaches are focused on injecting polymer for-
mulations at the tumor site, to create depots that enable localized
drug delivery [9].
As alternatives to lipids or polymers, peptide nanostructures are
attractive for biomedical applications [10e13] due to their chemical
versatility and the GRAS (generally recognized as safe) status
(21CFR72.320) of their amino acid breakdown products. One
example which is currently being assessed for clinical use are
peptide nanoﬁber scaffolds (PuraMatrix) for tissue engineering,
drug delivery and regenerative medicine [14,15]. In the current
work, we aim to generate liposome-like peptide nanocarriers able
to autonomously form nanoﬁbrous peptide depots at the tumor site
in response to enzymes secreted by cancer cells.
Targeting the enzymes that are over-expressed in cancer sites
provides a route towardsmore speciﬁc cancer nanocarriers [16e18].
In particular, a number of enzyme-responsive supramolecular ma-
terials have been developed that change their morphology upon
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enzyme action [19e24]. Matrix-metalloproteinases (MMPs) are
over-expressed in many types of cancer and are involved in
metastasis formation due to their ability to degrade the extracel-
lular matrix [25,26]. Due to this cancer-speciﬁc overexpression, the
enzymatic activity of MMPs provides opportunities to manage or
report cancer progression autonomously and only when and where
it is required [20,21,27e30]. MMPs are therefore logical targets for
enzyme-triggered therapeutics.
A variety of supramolecular assemblies (such as peptide am-
phiphiles [21,31e33] and polymer-peptide hybrids [34]) have been
developed that dissociate in response to MMP action. Typically,
these nanocarrier designs include a hydrophobic core that holds
the drug, which is then released in response to the MMP catalyzed
breakdown of the carrier. In an alternative approach, enzymatic
triggering by cell surface bound enzymes (phosphatases) results in
the formation of supramolecular nanoﬁber networks, providing
localized barriers around cancer cells that result in cell death
[22,35,36]. Enzyme-triggered morphology changes have been used
to drive the formation of aggregated, amorphous materials, which
selectively accumulate and retain polymer-peptide conjugates in
tumor tissues [20,37]. Recently, a combination therapy consisting of
enzyme (carboxylesterase) triggered peptide ﬁbrillization com-
bined with an anticancer drug (cisplatin) was shown to dramati-
cally enhance drug toxicity against drug-resistant cells [38].
The above examples clearly illustrate that supramolecular
peptide structures are well-suited to achieve enzyme-triggered
morphology transitions. We propose that the peptides may be
designed that combine a number of features of the above examples
into one system: (1) the peptides should form micelles with hy-
drophobic cores that can contain doxorubicin; (2) they should be
hydrolysable by MMP-9; (3) upon hydrolysis the amphiphilic bal-
ance should shift so that nanoﬁbers are formed, which incorporate
the doxorubicin (Fig. 1). This would allow for the formation of
micelles as mobile nanocarriers, which form localized depots in
areas where cancer-speciﬁc enzymes are secreted.
We designed our system by following design rules for MMP-9
speciﬁcity (MEROPS) in combination with the incorporation of
short b-sheet forming peptides (composed of just four-six amino
acids) into the MMP-9 substrate. In this way, hydrophobic pockets
(xFFyG, where x is either glycine or phenylacetyl group and y is
leucine or alanine) for doxorubicin entrapment and MMP-9 sub-
strates are incorporated in the nanocarrier structure. In order to
test whether these systems can indeed perform as autonomously
localized release systems (Fig. 1) both in vitro and in vivo tests were
performed. Ultimately, by using a xenograft mousemodel, we show
that localized formation of doxorubicin-containing ﬁbers slows
tumor growth compared to treatment with doxorubicin only. Our
approach uses a pathological hallmark of metastasis (MMP over-
expression) to guide therapeutic targeting, thereby turning a
negative prognostic indicator into a therapeutic response.
2. Materials and methods
2.1. Peptide synthesis
All peptides where synthesized using standard Fmoc solid phase
peptide synthesis on Wang resin pre-loaded with the ﬁrst amino
acid. Amino acid coupling was performed with a three-fold excess
of the Fmoc protected amino acid over the resin in DMF, using
N,N,N0,N0-Tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexa-
ﬂuorophosphate (HBTU) and N,N-Diisopropylethylamine (DIPEA)
as activating and coupling reagents in 1:2 ratio respectively relative
to the amino acid. Fmoc removal was carried out with 20% piperi-
dine in DMF. The cleavage of the peptides from the resin was ach-
ieved using a cleavage cocktail: 95% TFA, 2.5% triisopropylsilane
(TIS), and 2.5% water. The crude peptide was precipitated and
washed in cold diethyl ether and subsequently dissolved inwater to
allow further puriﬁcation. For the dissolution of hydrophobic se-
quences minimal amount of acetonitrile was used to ease the
dissolution of any non-dissolved material (in water). The samples
were then characterized by reverse phase high-performance liquid
chromatography (HPLC) and liquid chromatography-mass spec-
trometry (LCMS) to determine the purity and Mw of the product.
The peptides were puriﬁed by Almac Sciences (Elvingston Science
Center, Gladsmuir, East Lothian, Edinburgh, EH33 1EH, Scotland).
2.2. Nanostructure formation and characterization
The micelle forming peptide 2a was directly dissolved in
deionized water, the pH adjusted to 7.4 and its self-assembly
behavior investigated after a cycle of alternating sonication and
vortexing. For the expected enzyme cleavage peptide fragment i.e.
2b and the observed cleavage product (2c) the peptides were dis-
solved in deionized water and the pH was increased (NaOH 0.5 M)
to solubilize 2b/2c, followed by a slow decrease of pH achieved by
addition of HCl 0.5 M, to a ﬁnal pH of 6.5e7 to trigger gelation.
Gelation was observed for the expected MMP-9 cleavage product
2b and for the observed cleavage product 2c. Incorporation of
doxorubicin was achieved by solubilizing in DMSO by sonication
and a 1 mM stock solution in PBS was made and subsequent dilu-
tion into a suspension of peptide micelles.
2.3. Atomic force microscopy
AFM was performed using a Bruker, NanoScope V, Multimode 8
atomic force microscope. The samples were placed on a trimmed
and freshly cleaved mica sheet (G250-2 Mica sheets
1”  1”  0.006”) attached to an AFM support stub and left to air-
dry overnight in a dust-free environment, prior to imaging. All the
images were obtained using ScanAsyst in air mode. The resolution
of the scans is 512  512 pixels. Typical scanning speed was 1.0 Hz.
The images were analysed using NanoScope Analysis software
Version 1.50.
2.4. Transmission electron microscopy
TEM imaging was performed at the Advanced Science Research
Center (ASRC), CUNY Imaging Facility using a FEI, TITAN Halo
transmission electron microscope operating at 300 kV ﬁtted with
CETA 4 K  4 K camera. Carbon-coated copper grids (200 mesh)
were glow discharged in air for 30 s. 5 mL of sample was added to
the grid and blotted down using ﬁlter paper after 60 s. For double
staining, a negative stain (2% aqueous uranyl acetate) was applied
twice (30 s each time) and the mixture blotted again using ﬁlter
paper to remove excess. The dried specimens were then imaged.
2.5. Scanning electron microscopy
SEM imaging was performed at the University of Glasgow
Electron Microscopy facility. Cells were allowed to adhere on pre-
viously sterilized glass coverslips, serum starved overnight and
treated with 100 nM PMA to induce MMP-9 production. Then, they
were treated with 2.5 mM of peptide 2a for 72 h. After peptide
treatment, the cells were ﬁxed on glass coverslips using 1.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (1 h at 4 C). The
cells were then freeze-dried in liquid nitrogen. Samples were
subsequently sputter coated with gold (8 nm thick coating) under
vacuum and imaged using a JEOL-JSM 6400 ﬁeld emission scanning
electron microscope operated at an acceleration voltage of 10 kV.
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2.6. Confocal microscopy
Samples were imaged in a liquid state using a Nikon A1 (Tokyo,
Japan), an Olympus FV1000 (Leica, Milton Keynes, UK) or a LSM 880
with Airyscan (Zeiss, Jena, Germany) at the Beatson Cancer
Research Institute (Glasgow). Identical exposure times and pro-
cessing were used in all experiments. Images were acquired using a
405 nm laser for DAPI, 488 nm laser for carboxyﬂuorescein, and
561 nm for phalloidin (Alexa568 labeled), over a ﬁeld of view of 53
by 53 mm.
2.7. Cell culture, CRISPR and PMA stimulation
MDA-MB-231-luc-D3H2LN were cultured in Dulbecco's Modi-
ﬁed Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 2 mmol/L L-glutamine and penicillin/streptomycin
(100 units/mL and 100 mg/mL). Primers for sgRNAs sequences
were designed for human MMP-9 (http://crispr.mit.edu/, see SM)
and ligated into the BSMB1 cut vector lentiCRISPR [39]. Following
lentiviral vector production with VSV and sPAX2 packaging plas-
mids in HEK-293T cells, MDA-MB-231-luc-D3H2LN cells were
infected and subsequently selected using 1 mg/mL of puromycin.
Fig. 1. MMP-9 triggered micelle to ﬁber transition. (a) Schematic representation of micelle-to-ﬁber transition in the presence of cancer cells due to MMP-9 secretion, followed by
entrapment of doxorubicin in ﬁbrillar structures, which act as less mobile depots of the anticancer drug. (b) Chemical structure of the MMP-9 responsive peptide amphiphiles. (c)
TEM (negative staining with 2% aqueous uranyl acetate) and (d) AFM of peptidic nanocarriers (2a) showing micellar aggregates (starting material). (e) AFM image of MMP-9 induced
ﬁber formation (GFFAGL) (2c) after 96 h.
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For the stimulation of MMP-9 expression on glass/plastic with
phorbol mristate acetate (PMA), cells were washed 3 times with
PBS, serum starved and treated overnight with 100 nM of PMA.
2.8. Western blot and IHC analysis
The MMP-9 antibody (EP1255Y, Abcam) was used at a dilution
of 1:1000 for Western blotting of cell culture extracts and 1:200
on ﬁxed organotypic or subcutaneous tumor samples for immu-
nohistochemistry (IHC). For Western blot analysis, cells were
lysed using mRIPA buffer (50 mM Tris-HCl, 150 NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS and 10 mM EDTA) supplemented
with protease inhibitors aprotinin and leupeptin. After SDS-PAGE
and transfer to a nitrocellulose membrane (Perkin Elmer), a
chemiluminescence detection kit (Amersham) was employed in
conjunction with the HRP-linked anti-rabbit IgG antibody (NEB
7074, Cell Signaling) at a 1:10,000 dilution to detect MMP-9 and
GAPDH (2118, Cell Signaling) as a loading control. For IHC, stan-
dard processing and antigen-retrieval methods were applied
using citrate buffer (pH ¼ 6.0) and visualization and enhance-
ment of the secondary biotinylated HRP-linked antibody was
achieved by using the ABC Kit (Vectastain) and EnVision™ system
(DAKO).
2.9. Zymography
Precast 10% zymogram (gelatin) protein gels (Novex™, Ther-
moFisher Scientiﬁc) were loaded with 20 mL of tissue culture me-
dium, pre-spun at 1200 rpm for 5 min to remove cellular debris.
Following SDS-PAGE, gels were renatured and developed in the
respective buffers (Novex™) and ﬁnally developed for 24 h at 37 C.
Gels were then stained with SimplyBlue™ (ThermoFisher Scienti-
ﬁc) and scanned.
2.10. Cytotoxicity assay
For MTT analysis of proliferation and cytotoxicity of the MMP-9
responsive peptides alone or in conjunction with doxorubicin
(doxorubicin hydrochloride was used) on cells, 104 of MDA-MB-
231-luc-D3H2LN cells were seeded per well in a 96 well plate
format and allowed to settle overnight. The following day cells
were washed 3 times with PBS and serum starved in serum free
medium. They were then treated with 100 nM of PMA overnight
and exposed to increasing concentrations of the respective pep-
tides, doxorubicin alone or a combination of 2.5 mM of peptide plus
increasing concentrations of doxorubicin for 72 h. Following drug
exposure, 5 mL of MTT solution (5 mg/mL, Roche) was added per
well and incubated to produce formazan for 3e4 h. Finally 100 mL of
solubilization buffer (1:1 isopropanol:DMSO) was added, incubated
overnight at 37 C and the OD at 570 nm determined using a
microplate reader (Saﬁre 2, Tecan).
2.11. Organotypic culture matrices
Organotypic matrices and subsequent invasion assay was per-
formed as described previously [40]. Brieﬂy, 105 primary human
ﬁbroblasts, between the passages 4e8, were embedded in rat-tail
extracted collagen. The detached polymerized mixture was
allowed to contract into a malleable 3D matrix for up to 14 days in
DMEM supplemented with 10% FBS and 2 mmol/L L-glutamine.
1  105 of MDA-MB-231-luc-D3H2LN were seeded on top of the
matrices and left to settle for 24 h. They were then mounted unto
a metal grid and an air-liquid-interface created allowing for the
invasion process to start. After 3 days the medium below the grid
was collected for the MMP-9 activity assay and the cultures ﬁxed
in 4% paraformaldehyde, followed by parafﬁn embedding and
processing for haematoxylin and eosin staining. Blank sections
were further stained with a-MMP9 antibody (EP1255Y, Abcam) for
the visualization of MMP-9 expression in and around invading
cells.
2.12. In vivo assessment of MMP-9 responsive peptides
2  106 cells were re-suspended after trypsinisation in 100 mL
Hank's Balanced Salt Solution (HBSS, Invitrogen) and injected
subcutaneously into the ﬂanks of CD1/ nude mice. Tumors were
allowed to develop to a size of 280e400 mm3 before the
commencement of treatment. Animals were kept in a conventional
animal facility and all experiments were carried out in compliance
with the U.K. Home Ofﬁce guidelines. Tumor bearing mice were
treated with daily subcutaneous injections of either the vehicle 1:1
DMSO:PBS or a sub-clinically active dose of doxorubicin 1 mg/kg
alone or in conjunction with the respective peptides at a concen-
tration of 36 mg/kg. The tumor sizes were monitored every second
day by caliper measurements and the tumor volume calculated
using the ellipsoid formula [41].
2.13. MMP-9 activity assay
The activity of the MMP-9 was assessed using the SensoLyte®
Plus 520 MMP-9 assay kit (Anaspec, Fremont, CA). Brieﬂy, cell
culture supernatants were collected after overnight serum expo-
sure, serum starvation followed by stimulation with 100 nM PMA
and 3 day invasion into organotypic matrices and centrifuged for
10 min at 1000 g, 4 C. A black 96-well plate covered with MMP-9
antibodies was subsequently used to capture the (pro-)MMP-9
from the sample supernatant. An activation step with APMA (2 h)
was performed in order to activate pro-MMP-9 and record a total
signal of potential MMP-9 activity. After activation the assay sub-
strate (5-FAM/QXL™ 520 FRET) was added and the ﬂuorescence
reading performed using a X-Fluor Saﬁre 2 ﬂuorescence plate
reader (lex/lem 490 nm/520 nm). The amount of MMP-9 in each
sample was calculated according to the manufacturers instruction
on the basis of a standard curve of the catalytic responsive enzyme.
The assay was performed in 3 independent experiments for each
condition.
2.14. Inverted invasion assay
Transwell inserts with a pore size of 0.8 mm were used as
described previously in an inverted invasion assay [42]. To that end,
Matrigel (BD) was diluted with PBS to a concentration of 5 mg/mL
and allowed to polymerize in the transwell at 37 C for 30 min.
Following this, MDA-MB-231-luc-D3H2LN cells expressing a GFP
construct were seeded at a density of 5  104 cells on the inverted
insert, directly on the porous membrane. Cells were allowed to
adhere for up to 4 h and inserts placed upright into 24 well plates
containing serum free medium alone or in combination with the
peptides 1a, 2a and the respective D-peptide versions. DMEM plus
10% FBS and supplemented with 25 ng/mL EGF was added atop the
Matrigel, establishing a FBS þ EGF gradient across the Matrigel and
cells allowed to invade for up to 5 days. Confocal microscopy was
used to visualize the cells that crossed through the porous ﬁlter and
optical sections acquired in 15 mm steps. For this, an inverted
confocal microscope (Fluoview FV1000, Olympus) equipped with
the acquisition software FV10-ASW1.7 was used. The measured
ﬂuorescent intensity was subsequently used to quantify the per-
centage of invading cells/relative invasion index past 30 mm into the
Matrigel versus the total ﬂuorescence intensity in all sections uti-
lizing the ImageJ plugin Area Calculator.
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3. Results and discussion
3.1. MMP-9 triggered micelle to ﬁber transition for entrapment of
doxorubicin
Recent examples demonstrate the integration of enzymatic ac-
tivity and molecular self-assembly (biocatalytic self-assembly) for
the development of cancer therapy [22,35,38]. Typically, the mo-
lecular design of these structures involve hydrophobic (naphtha-
lene, ﬂuroenyl, lipidic) or polymeric moieties. We aimed to design a
system that does not contain new chemical entities, focusing on
alpha peptides, because of their inherent biocompatibility and
biodegradability through proteolytic digestion to alpha amino
acids. Thus, we designed peptide micelles for drug encapsulation,
which reconﬁgure to less mobile ﬁbrillar structures with selective
tumor retention due to localized MMP-9 activity (Fig. 1a).
The design of the peptide sequence is based onMMP-9 triggered
gelation reported by Xu and co-workers [27] and our previous work
on MMP-9 induced micelle-to-ﬁber transitions of PhAc-FFAGLDD
(1a) [43]. In addition, a peptidic GFFLGLDD analogue was
designed (2a, not containing the phenylacetyl moieity) containing
the ﬁber forming (GFFL/G) unit, the expected MMP-9 cleavable
bond (GYL) and the reconﬁguration (DD) unit. For this design, the
MEROPS database [44] was consulted, where the self-assembling
units are incorporated into the MMP-9 substrate.
Peptides 1a/b and 2a/b/cwere synthesized and characterized for
self-assembly behavior (for HPLC andmass spectroscopy details see
Figs. S1eS3). The characterization of peptide 1a and 1b alongside
with the MMP-9 digestion of 1a was previously reported [43]. The
enzymatic cleavage of 2awas assessed by treatment withMMP-9 at
a concentration of 50 ng/mL [45,46], which is in the range of the
MMP-9 concentration secreted by cancer cells determined in our
experiments (see below). The conversion and product identiﬁca-
tion were assessed by HPLC and LCMS (Figs. S7 and S8). The near-
complete enzymatic digestion of GFFLGLDD occurs between 48
and 96 h. Peptide 2a shows conversion to a range of products, the
main one being GFFLGL (2c), corresponding to the fragment that is
one residue longer than the expected product, as previously
observed with 1a [43], indicating a shift in MMP-9 speciﬁcity
(Fig. 1b) [47]. Other products that formed, but in lower quantities
are GFF (þLGLDD) and (GF) þ FLGLDD (Figs. S7 and S8). These re-
sults show that there is some residual cleavage by MMP-9 at the
FYL and FYF bonds and is in accordance with previously observed
ability of MMP-9 to cleave amyloid peptides [27,48,49]. As expected
for amphiphilic compounds, AFM and TEM characterization of the
precursors revealed spherical aggregates for 2a (Fig. 1c and d). In
contrast, chemically synthesized positive controls for compounds
2b (Fig. S4a) and 2c (Fig. S5a), produced ﬁbrillar nanostructures.
Themorphological change induced by enzymatic cleavagewas then
monitored by AFM and TEM, conﬁrming that upon enzymatic hy-
drolysis the micelles reconﬁgured into ﬁbers, which were similar to
those formed by the chemically synthesized cleavage products
alone (Fig. 1e and Fig. S9). Thus, peptide 2a is capable of undergoing
MMP-9 triggered morphological micelle-to-ﬁber transition (Fig. 1c,
d, 1e and Fig. S 9b), as reported previously for 1a (also shown in
Fig. S9a) [43].
The differential supramolecular organization underpinning this
shape change was investigated by infrared (IR) spectroscopy
(Figs. S4b and S5b), which suggested the presence of ordered
structures [50]. Peptide 2a shows a red shift (broad peak at
1643 cm1) compared to absorption values typical for free peptides
in solution (1650e1655 cm1). The 1570e1580 cm1 absorption
band is attributed to the aspartic acid side chain carboxylate group
present in 2a. Extended structures are observed for 2b (1630 cm1)
showing a complex pattern [51]. b-sheet like structures were found
for 2c indicated by the presence of 1625 cm1 peak (Fig. S5b).
Having established that the peptides were capable of undergo-
ing a morphological change in response to MMP-9 activity, we next
investigated whether a therapeutic drug could be encapsulated
within the nanostructures. For this purpose, doxorubicin was sol-
ubilized in DMSO by sonication and a 1 mM stock solution in PBS
was made and subsequently diluted into the suspension of peptide
micelles (ﬁnal concentration of doxorubicin: 5 mM). First, the effect
of doxorubicin incorporation on the biocatalytic micelle-to-ﬁber
conversion was investigated. To this end, the starting material
(2a) and the observed product of MMP-9 cleavage (2c) were char-
acterized by AFM and TEM in the presence of 0.2% of doxorubicin, to
assess whether the micelle or ﬁber formation was disrupted by the
presence of the drug. In the presence of doxorubicin, spherical
aggregates are still observed for 2a (Fig. S6a and S6b), and ﬁbers for
2c (Fig. S6d and S6e), Doxorubicin ﬂuorescence was also imaged to
assess whether the drug was incorporated in the nanostructures.
Fluorescence signal (Fig. S6c and S6f) from doxorubicin emission is
observed in both 2a and 2c, conﬁrming its incorporation in peptide
nanostructures. Confocal microscopy (Fig. S10b) conﬁrms doxoru-
bicin entrapment in the ﬁbres after enzyme treatment, which is
further conﬁrmed by ﬂuorescence studies (Fig. S10a), where a two-
stage discontinuous behavior is shown upon treatment of peptide
micelles with MMP-9. Due to difﬁculties in separating peptide
fragments and doxorubicin, it was not possible to quantitatively
determine the doxorubicin loading in the peptide nanostructures.
3.2. Treatment with MMP-9 responsive peptides combined with
doxorubicin in vitro
Supramolecular peptide based systems have recently been
shown to be successful for in vitro and in vivo inhibition of tumor
progression based on polymeric nanocarriers (micellar peptide/
polymer drug conjugates) [20] or formation of hydrophobic
(NapFF), cytotoxic ﬁbres [52]. Our approach differs in that we use
peptidic nanocarriers to locally assemble into non-toxic nano-
structured depots. To measure the response of the MDA-MB-231-
luc-D3H2LN cells to the peptide micelles in vitro, cells had to ﬁrst
be serum starved in order to avoid the effect of non-speciﬁc
cleavage by MMP-like enzymes contained in serum [53,54]. They
were subsequently stimulated with 100 nM of PMA (Phorbol 12-
myristate 13-acetate) in order to express MMP-9, which is
secreted by cancer cells to promote 3D invasion [55] (Fig. 2a). Zy-
mograms of the gelatinolytic properties of cell culture supernatants
from the cancer cells showed the presence of several MMPs in the
serum sample (with bands at around 90 and 70 kDa as expected for
MMP-9 and MMP-2 respectively). Serum starved cells treated with
PMA, however, only displayed a single degradation band at
~90 kDa, the expected size of MMP-9 (Fig. 2b). Speciﬁc MMP-9
cleavage activity was assessed by the use of a ﬂuorimetric ELISA,
showing that after PMA stimulation 18.5 ± 4.1 ng/mL of active
enzyme could be detected (Fig. 2c).
Biocompatibility of MMP-9 cleavable peptides was then
measured in cancer cells by the use of MTT assays. In addition, the
non-cleavable D-stereoisomer analogues PhAc-DFDFDAGDLDD
(1a(D)) and GDFDFDLGDLDD (2a(D)) were synthesized (Figs. S11 and
S12) for comparisonwith the L-stereoisomers. The D-stereoisomers
treated with MMP-9 showed no degradation for at least 10 days of
treatment (Figs. S13 and S14). MTT assay showed no reduction in
viability, while instead a slight increase in proliferation for 1a,1a(D)
and 2a(D) (Fig. 2d, >100%). A minor reduction of cell viability for 2a
(Fig. 2d and 78.3 ± 14.5%) was observed at concentrations above the
critical aggregation concentration of 2.5 mM.
When cells were treated with 2.5 mM of peptide micelles in
conjunction with increasing concentrations of doxorubicin, an
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increased toxicity was observed especially for the MMP-9 cleavable
peptides 1a and 2a (Fig. 2eeh). Critically, this behavior was not
observed for the D-stereoisomers of the peptides, 1a(D) and 2a(D),
that are not susceptible to MMP-9 digestion (Figs. S13 and S14),
therefore themicelle-to-ﬁbre transition does not occur. In Fig. 2eeh
the observed 60%e70% of viability in the doxorubicin treated
samples is preserved in the combination treatments of D-peptide
with doxorubicin. In the case of the L-peptide and doxorubicin
combination the cell viability is drastically reduced to 37.5% and
35% for 1a and 2a, respectively.
Up to 5 mM peptide concentrations, both peptide micelle types
1a/2a were found to have minimal effects on cell viability in the
absence of doxorubicin (Fig. 2d). However, both peptides showed to
increase the effectiveness of doxorubicin over a wide range of
concentrations (6.25e500 nM) (Fig. 2e and f). In contrast, neither of
the non-hydrolysable D-stereoisomers showed this ampliﬁcation of
the effects of doxorubicin treatment. 1a(D) even reduced the
effectiveness of doxorubicin treatment, consistent with the idea
that doxorubicin could be trapped by peptide micelles, but not
released through enzymatic cleavage. Thus, the combination
treatment was more toxic to cancer cells compared to doxorubicin
alone and also compared to the combination of the D-peptides and
doxorubicin, conﬁrming the crucial role of MMP-9 in micelle-
mediated drug delivery. These data support a mechanism,
whereby the micelle-to-ﬁbre morphology transition results in
increased toxicity of the combination treatment due to the for-
mation of ﬁbrillar depots which act to localize the drug near the
cancer cells.
Fig. 2. Effect of MMP-9 cleavable peptides and doxorubicin on proliferation of cells in vitro. (a) MMP-9 expression in MDA-MB-231-luc-D3H2LN cells after serum starvation (SF)
and stimulation with PMA (100 nM). (b) Zymogram of the gelatinolytic activity of cell culture supernatants of MDA-MB-231-D3H2LN cells before and after serum starvation
(SF) ± 100 nM of PMA. (c) Speciﬁc MMP-9 activity was quantiﬁed for MDA-MB-231-luc-D3H2LN cells in serum and when cells were stimulated with 100 nM of PMA, by ﬂuorimetric
ELISA (bars: mean; error bars: SEM; *p < 0.05 by standard student's t-test; n ¼ 3 independent experiments). (d) MTT assay of MDA-MB-231-luc-D3H2LN cells after serum starvation
(SF) and stimulation with PMA (100 nM) exposed to increasing concentrations of MMP-9 cleavable peptides 1a, 2a and their D-peptide versions after 3 days of incubation. (e) þ (f)
Combination treatment of cells with peptides 1a and 2a with doxorubicin at 2.5 mM of the respective peptide and histogram overview of results obtained at 2.5 mM
peptides ± 200 nM doxorubicin (g) þ (h), measured by MTT assay after 3 days (bars/dots: mean; error bars: SEM; *p < 0.05, ***p < 0.001 by standard student's t-test; n ¼ 3
independent experiments).
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3.3. Visualization of peptide nanostructures in vitro
Imaging exogenous peptide nanostructures in the proximity of
cells was challenging, mainly because of the lack of intrinsic
ﬂuorescence of the peptide assemblies. Signal visualization by
confocal microscopy was achieved by co-assembling small per-
centage (1%) of ﬂuorescently tagged peptide-conjugates with
micelle forming peptides [56,57]. To this end, peptide 2a was
labeled with carboxyﬂuorescein. Carboxyﬂuorescein-2a (lex/
em ¼ 492/517 nm) and 2a co-assemblies were prepared by mixing
the two molecules at a ratio of 1/100, followed by sonication. They
were imaged using AFM, TEM and ﬂuorescence microscopy
(Fig. S15). These results show that the carboxyﬂuorescein-2a and
2a co-assemble into spherical aggregates and that carboxy-
ﬂuorescein is incorporated in the micelles, which made it a good
candidate for imaging the distribution of peptides after adminis-
tration to cells (Fig. 3a).
The imaging of peptides, by laser-scanning confocal microscopy
with subsequent deconvolution using an Airyscan unit (Zeiss), in
proximity to cancer cells in vitro shows that the peptidic carriers are
found in the cytoplasm and nuclei of the cancer cells (pink arrows)
with some larger aggregates (orange arrows) also detected outside
the cells. The formation of ﬁbrillar nanostructures becomes
apparent in the larger aggregates outside of the cell which was
further conﬁrmed by SEM (Fig. 3b).
Resolution limitations of confocal microscopy make it difﬁcult
to be conclusive on peptide morphology (micelles or ﬁbres) in
proximity to cancer cells. However, signal detection is useful for
conﬁrmation of the peptides positioning in proximity of cancer
cells. Moreover, substantial peptide uptake can be noticed (Fig. 3a,
Fig. 3. Imaging of peptides in proximity of cancer cells in vitro, with loss of aggregate ﬁbrillar morphology observed upon MMP-9 knockout. (a) 2D Airyscan captured
representative image of MDA-MB-231-luc-D3H2LN breast cancer cells cultured for 3 days in the presence of 2a þ 2a-carboxyﬂuorescein (green) and 100 nM PMA, inducing MMP-9
expression. The actin cytoskeleton was stained with phalloidin-Alexa568 (red) and the nuclei with DAPI (blue). Extra-cellular peptidic aggregates were further magniﬁed and ﬁbrillar
features highlighted (white arrows). Spherical bodies of the peptidic carrier were detected in and around the cancer cells as well as ﬁbrillar aggregates formed (orange arrows); with
accumulation of the peptides in the cytoplasm and nuclei of cells (pink arrows); (b) Extracellular aggregates of peptide 2a visualized by SEM; (c) þ (g) Airyscan captured
representative images of peptidic structures around MDA-MB-231-luc-D3H2LN MMP-9 KO and WT cells treated and stained as in (a); Extra-cellular peptidic aggregates were
further magniﬁed (d) þ (h); representative immunoblots shown for MMP-9 expression for both KO and WT cells (e) þ (i) as well as zymograms of the gelatinolytic activity of cell
culture supernatants after serum starvation (SF) and stimulation with PMA (100 nM) (f) þ (j); scale bars: 5 mm.
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g). Furthermore, the genetic editing and deletion of MMP-9
expression using CRIPSR-Cas9 technology, goes on to demon-
strate the need of MMP-9 presence around the cells in order for
spherical, micellar aggregates to be efﬁciently converted into
ﬁbrillar network-like nanostructures (see Fig. 3c and d versus 3 g
and 3 h).
3.4. Treatment with MMP-9 responsive peptides augments
doxorubicin toxicity in vivo
After showing the synergistic effect of peptide amphiphiles
loaded with doxorubicin in vitro and demonstrating formation of
ﬁbrillar aggregates in proximity of MMP-9 secreting cells, we
moved on to investigate whether the doxorubicin loaded peptide
carriers could increase the effectiveness of doxorubicin in vivo.
First, an in vivo imaging dye to visualize MMPs, MMPSense680™,
was injected intravenously and imaged 2 h after injection in MDA-
MB-231-luc-D3H2LN developed xenograft tumors, revealing high
MMP activity at the primary tumor site (Fig. 4a). MMP-9 expres-
sion has been demonstrated in primary human breast cancer tu-
mors samples before by IHC (Immunohistochemistry) [58]. Here,
the presence of MMP-9 was also visualized by IHC in the devel-
oped xenograft tumors and found to be increased at the invasive
border of the subcutaneous tumors (Fig. 4b). In order to assess the
effect of MMP-9 cleavable peptidic carriers on the delivery and the
effect of sub-clinically administered doses of chemotherapeutics,
nude mice were allowed to develop primary tumors of a size
between 280 and 400 mm3. They were then grouped randomly
into treatment groups of 3e4 mice, receiving daily subcutaneous
(s.c.) injections, distal to the primary tumor site, of either the
Fig. 4. MMP-9 cleavable peptide carriers augment doxorubicin treatment in vivo. (a) MMPSense680™ reporting on MMP activity in vivo in a subcutaneous tumor of MDA-MB-
231-luc-D3H2LN. (b) Representative H&E and IHC of human MMP-9 expression at the invasive border of a MDA-MB-231-luc-D3H2LN subcutaneous xenograft tumor; scale bars:
100 mm. (c) þ (e) In vivo tumor progression of MDA-MB-231-luc-D3H2LN subcutaneous tumors treated with 1a (c) or 2a (e) (36 mg/kg), doxorubicin at a low concentration (1 mg/
kg) or in combination of the two, by s.c. injection, showing stasis of tumor growth in the combination treatment. (d) þ (f) Treatment with D-peptides did not result in an additive
effect (arrows: time points of treatment; data point: mean; error bars: SEM; n ¼ 3e4 mice per treatment group; *p < 0.05 and **p < 0.01 by standard student's t-test).
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control (1:1 PBS:DMSO), a sub-clinically effective dose of doxo-
rubicin (1 mg/kg) [59,60], the respective peptide carrier (36 mg/
kg), or a combination of the two. This revealed that the MMP-9
cleavable peptide carriers 1a and 2a augment doxorubicin
toxicity when administered in tandem. When compared to the
doxorubicin only treatment cohort, the peptide carrier/doxoru-
bicin treatment, especially with 2a, shows to render the tumors in
a static progression (Fig. 4c and e). Furthermore, the treatment
with only 1a had no effect on tumor progression, while 2a seemed
to have some delaying effect on tumor growth. This differential
effect on tumor growth is in agreement with in vitro results
showing reduced cell growth in the presence of 2a (Fig. 2g/h). On
the other hand, the D-peptide versions of both, 1a(D) and 2a(D), as
well as their combination with doxorubicin, had no effect on tu-
mor progression (Fig. 4d and f). In fact the combination of the D-
peptide with the doxorubicin seems to hamper the effect of the
chemotherapeutic, compared to when solely doxorubicin was
administered, suggesting doxorubicin is not effectively released
from the micellar precursors. This demonstrates that MMP-9
cleavable peptide carriers in conjunction with doxorubicin have
an increased effect on toxicity toward the developed tumor mass.
In addition to the tumor site speciﬁc cleavage of the peptide mi-
celles and the local release of the chemotherapeutic, the observed
increased toxicity of the combination treatment could be attrib-
uted to the possibility of forming reservoirs of doxorubicin at the
MMP-9 rich tumor site, with the cleaved peptidic carrier incor-
porating doxorubicin when forming ﬁbers, as observed in vitro.
3.5. Invasion of MDA-MB-231-luc-D3H2LN is signiﬁcantly
decreased in the presence of MMP-9 responsive peptide carriers
MMP-9 has previously been found to be up-regulated and
associatedwith invasiveness of the breast cancer cell lineMDA-MB-
231 [61e63]. Expression of, for example a3b1 integrin, on invading
MDA-MB-231 cells has been found to be a key regulator in the
expression of MMP-9 during invasion of these cancer cells [61].
Indeed here, MMP-9 expression was detected in organotypic
matrices, a 3D invasion model, by IHC, after MDA-MB-231-luc-
D3H2LN cells had invaded for up to 5 days into the collagen matrix
(Fig. 5a). Further, the activity of speciﬁcally MMP-9 in the culture
medium of the organotypic matrices was measured by ﬂuorimetric
ELISA, following three days of invasion of the MDA-MB-231-luc-
D3H2LN cells (Fig. 5b). Notably, MMP-9 expression has previously
been found to be particularly stimulated when MDA-MB-231 cells
came in contact with extracellular matrix components and espe-
cially matrigel in vitro, potentially aiding invasion [62]. Due to the
fact that we observed increased MMP-9 expression at the invasive
edge of the subcutaneous tumors (see Fig. 4b), we wanted to assess
whether the peptides themselves had any effect on the invasion of
cells. In order to assess the effect on invasion of the MMP-9
cleavable peptidic carriers alone, MDA-MB-231-luc-D3H2LN cells
were allowed to invade in an inverse invasion assay, containing
matrigel, for up to 5 days (Fig. 5c) [42]. Cells exposed to 2.5 mM of
either peptide 1a or 2a showed a signiﬁcant reduction in their in-
vasion (Fig. 5d). Scanning Electron Microscopy (SEM) further
Fig. 5. The effect of MMP-9 cleavable peptides on the invasion of cells. (a) IHC of MMP-9 of invading MDA-MB-231-luc-D3H2LN on an organotypic matrix; scale bars 100 mm. (b)
MMP-9 activity was quantiﬁed for MDA-MB-231-luc-D3H2LN in serum and when cells are seeded on an organotypic matrix, by ﬂuorimetric ELISA (bars: mean; error bars: SEM;
*p < 0.05 by standard student's t-test; n ¼ 3 independent experiments). (c) Schematic of an inverted invasion assay set-up, with the GFP expressing cells (green) on the bottom of
the insert in serum free medium (pink), migrating toward a serum and EGF gradient (serum þ EGF containing medium in brown) into the matrigel (blue). (d) Inverse invasion assay
of MDA-MB-231-luc-D3H2LN expressing a GFP construct, invading into matrigel, with 0 mm denoting cells that have gone through the ﬁlter but not into the gel, quantiﬁed by
measuring the ﬂuorescence intensity of cells penetrating above 30 mm (bars: mean; error bars: SEM; **p < 0.01 by standard student's t-test; n ¼ 3 independent experiments). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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showed an alteration in the lamellipodia formation of the cells
stimulated with PMA and treated with the L-peptide 2a, but not the
D-peptide 2a, indicating possible hindrance of migration (Fig. S16).
Further, the quantiﬁcation of circulating tumor cells (CTCs) in the
blood of the xenograft mice was performed. CTCs have an impor-
tant role as markers of tumor progression and as such could be
applied to reveal drug resistance in real time [64]. Here, we
observed a rescue effect of combination treatment of doxorubicin
and 2a compared to the elevated number of CTCs measured for
doxorubicin treatment alone (Fig. S17). Having shown that MMP-9
expression is particularly prominent at the tumor border of xeno-
graft subcutaneous MDA-MB-231-luc-D3H2LN tumors, the treat-
ment with these peptidic carriers could localize drug delivery and
retentions at these crucial sites of tumor progression. The addi-
tional effect of the treatment with the peptides alone hindering
invasion in a 3D in vitro assay could be another beneﬁt of treating
the primary tumor with the peptidic carrier, potentially hampering
metastatic dissemination.
4. Conclusions
In summary, peptides may act as ‘safe’ and highly tuneable
building blocks of nanostructures, which are attractive due to low
toxicity of their degradation products. Therefore, peptides and
polymer-peptide conjugates gained attention in the last two de-
cades as designable alternatives to liposomal nanostructures that
have reached the clinic as doxorubicin vehicles for cancer treat-
ment (example Doxil). More recently, nanoscale peptide vectors
used for physical encapsulation of anticancer drugs were able to
show better performance compared to the drugs only [38,65,66].
Here, two different MMP-9 responsive peptide amphiphiles able to
self-assemble into spherical aggregates that undergo enzyme
triggered micelle to ﬁber transition and are capable of encapsula-
tion and controlled release of doxorubicin are presented. These
mobile carriers of anticancer drugs are designed to selectively
deliver the payload to tumor tissues, where they assemble to form
localized ﬁbrous depots by exploiting invasive border associated
MMP-9 overexpression. The assembled ﬁbers provide a depot for
prolonged drug delivery due to partial entrapment of the drug and
the intrinsic biodegradable nature of peptide carriers themselves.
Unlike previously reported peptide conjugates, these systems have
the advantage of being non-toxic to cells (as shown by MTT assay)
and can be used as carriers for doxorubicin in vivo. When tested on
xenograft tumor models, the cancer growth was halted by admin-
istration of doxorubicin loaded peptide nanostructures. In contrast
to the combination therapies, where the peptide on its own has a
toxic effect, here, the peptides themselves are non-toxic and are
used as nanocarriers that can enhance the effectiveness of doxo-
rubicin, trapped within the peptide nanostructure. This approach
opens up the possibility of developing new (enzyme responsive)
drug delivery vehicles designed to release drug payload locally, in
the presence of the desired enzyme with potential application in
cancer therapy.
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Figure S 1. Peptide synthesis and characterization of 2a. (a) chemical structure of 2a 
with mass analysis. (b) 2a peptide sequence was analyzed by HPLC (20-80% Solvent B) 
and shows a retention time of 16.8 min. (c) LCMS results are as follows: LC (5-100% 
Solvent D, retention time =10.1 min) and MS (mass calculated: [M-H]-= 881.4, mass 




Figure S 2. Peptide synthesis and characterization of 2b. (a) chemical structure of 2b 
with mass analysis. (b) 2b peptide sequence was analyzed by HPLC (20-80% Solvent B) 
and shows a retention time of 15.6 min. (c) LCMS results are as follows: LC (5-100% 
Solvent D, retention time = 10.1 min) and MS (mass calculated: [M+H]+= 540.3, mass 




Figure S 3. Peptide synthesis and characterization of 2c. (a) chemical structure of 2c 
with mass analysis. (b) UPLC (data provided by CEM) results are as follows: retention 







Figure S 4. Self-assembly characterization of 2b. (a) Atomic force microscopy (AFM) 
showing fibres (hydrogels – 20 mM) for 2b. (b) FTIR absorption spectrum in the amide I 




Figure S 5. Self-assembly characterization of 2c. (a) AFM showing fibres for 
hydrogels (20 mM) for 2c. (b) FTIR absorption spectrum in the amide I region (D2O, pH 






Figure S 6. Self-assembly characterization in presence of doxorubicin. (a) TEM, (b) 
AFM and (c) fluorescence microscopy (magnification 10x) images of doxorubicin loaded 
octapeptide  (2a) showing that micelle formation was not disrupted by the presence of the 
drug (doxorubicin) and that the doxorubicin (fluorescence microscopy) is retained in the 
micelles. (d) TEM and (e) AFM showing the synthetically made observed cleavage 
product (2c) confirming fibers are forming in presence of doxorubicin and (f) 
fluorescence microscopy (magnification 10x) showing doxorubicin entrapment in the 




Figure S 7. HPLC of peptide (2a) digestion with MMP-9. HPLC chromatograms 
showing the MMP-9 induced digestion of 2a monitored over 120 h. Product formation at 
different time points is showed: time 0 (no enzyme), 24 h, 48 h. 72 h, 96 h and 120 h. 
More in detail, GFFLGLDD is converted to 3 main products after 96 h: GFFLGL (2c): 
HPLC (20-80% Solvent B, retention time = 18.9 min). LCMS: LC (5-100% Solvent D, 
retention time = 10.3 min), MS (mass calculated: [M-H]-= 651.3, mass observed: [M-H]- 
= 651.3); GFF (2d): HPLC (20-80% Solvent B, retention time = 14.1 min). LCMS: LC 
(5-100% Solvent D, retention time = 8.6 min), MS (mass calculated: [M-H]-= 368.1, 
mass observed: [M-H]- = 368.1); FLGLDD (2e): HPLC (20-80% Solvent B, retention 
time = 13.7 min). LCMS: LC (5-100% Solvent D, retention time = 8.5 min), MS (mass 
calculated: [M+H]+= 679.3, mass observed: [M+H]+ = 679.3). After 120 h further 
fragmentation of the substrate is observed, but also the digestion of the GFFLGL product 
(2c) into GF and FLGL (2f): HPLC (20-80% Solvent B, retention time = 17.2 min). 
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LCMS: LC (5-100% Solvent D, retention time = 9.3 min), MS (mass calculated: [M-H]- 





Figure S 8. Mass spectra of peptide (2a) digestion with MMP-9. MS data for (a) 
GFFLGL (2c), (b) GFF (2d), (c) FLGLDD (2e) and (d) FLGL (2f) described in the 




Figure S 9. TEM images. (a) 1a and (b) 2a treated with MMP-9 for 96 h to form fibers 
of 1c and 2c, respectively.   
 
  
Figure S 10. Doxorubicin fluorescence. (a) Fluorescence intensities of doxorubicin 
monitored over time for doxorubicin only, doxorubicin loaded into precursor peptide (2a) 
micelles and MMP-9 treated precursor peptide (2a) micelles loaded with doxorubicin. (b) 
Confocal microscopy after MMP-9 treatment confirming that the doxorubicin is trapped 




Figure S 11. Peptide synthesis and characterization of 1a(D). (a) chemical structure of 
1a(D) with mass analysis. (b) 1a(D) peptide sequence was analyzed by HPLC (20-80% 
Solvent B) and shows a retention time of 22.5 min. (c) MS (mass calculated: [M-H]-= 




Figure S 12. Peptide synthesis and characterization of 2a(D). (a) chemical structure of 
2a(D) with mass analysis. (b) 2a(D) peptide sequence was analyzed by HPLC (20-80% 
Solvent B) and shows a retention time of 17.5 min. (c) MS (mass calculated: [M-H]-= 








Figure S 13. HPLC of peptide 1a D treated with MMP-9 for 10 days to assess 
stability. HPLC chromatograms showing the resistance of 1a D to MMP-9 digestion 
monitored at (a) time 0 (no enzyme), (b) 96 h and (c) 240 h. 1a (D) peptide sequence was 
analyzed by HPLC (30-50% Solvent B, 70 min) and shows a retention time of 35.1 min 






Figure S 14. HPLC of peptide 2a D treated with MMP-9 for 10 days to assess 
stability. HPLC chromatograms showing the resistance of 2a D to MMP-9 digestion 
monitored at (a) time 0 (no enzyme), (b) 96 h and (c) 240 h. 2a (D) peptide sequence was 
analyzed by HPLC (20-80% Solvent B, 45 min) and shows a retention time of 17.5 min 





Figure S 15. Co-assembly of 2a with 1% of carboxyfluorescein-2a for visualization. 
In order to visualize the peptide distribution in presence of cells, the co-assembly of 2a 
with 1% of carboxyfluorescein-2a was studied and characterized by AFM, TEM and 
fluorescence microscopy. (a) AFM, (b) TEM (scale bar: 100 nm), (c) and (e) 
fluorescence microscopy (magnification 10x) of the co-assembled structures formed by 




















Figure S 16. Effect of the MMP-9 cleavable peptide 2a on cell morphology in vitro. 
Altered lamellipodia morphology upon PMA stimulation after 3 day treatment with 2.5 
mM of peptide 2a (D) or 2a visualized by SEM; top panel, bar: 10 μm; lower panel 





Figure S 17. MMP-9 cleavable peptide carrier 2a rescues effect of doxorubicin 
treatment on circulating tumor cells. A Quantification of circulating tumor cells in the 
blood of subcutaneous tumor bearing nude mice by RT-PCR, measuring human GAPDH 
levels normalized to murine beta-2-microglobulin; bars: mean of fold change. Error bars: 






High-performance liquid chromatography. HPLC analyses of peptides were 
performed using Dionex P680 HPLC system equipped with a Macherey-Nagel C18 
column of 250 mm length, 4.6 mm internal diameter and 5 mm particle size equipped 
with UV-Vis detector. The gradient: (Solvent A: 0.1% TFA in water; Solvent B: 0.1% 
TFA in acetonitrile) 20-80% B was utilized, with each run lasting a total of 46 minutes 
using a flow rate of 1 mL min-1 and detection wavelengths set at 214 nm and 254 nm 
using the UV-Vis detector. For separation of peptides 1a and 1c a 30-50% B gradient was 
utilized with each run lasting a total of 70 minutes using a flow rate of 1 mL min-1 and 
detection wavelengths set at 214 nm and 254 nm using the UV-Vis detector. 
 
Liquid chromatography-mass spectrometry. LC-MS obtained at the University of 
Strathclyde Mass Spectrometry facility was used to confirm peptide molecular weights. 
All analyses were carried out on a reverse-phase 15 cm Kinetex C18, 150 x 4.6 mm, 5 
micron column. The LC-MS instrument was an Agilent 1200 Series HPLC, coupled to an 
Agilent 6130 Dual source MS detector. The gradient: (Solvent C: 5 mM ammonium 
acetate in water; Solvent D: 5 mM ammonium acetate in  acetonitrile) 0-3 min 5% D, 3-
17 min 5-100% D, 17-27 min 100% D, 27-33 min 100-5% D, and 33-36 min 5% D was 
used in all analyses; the flow rate was set at 1 mL min-1 and detection wavelengths at 214 
nm. Mass detection was set to analyse in Scan mode with electrospray ionisation (MM-
ES+APCI).  For all peptides examined both positive and negative ions were detected but 
only one (positive or negative ion) is shown for peptide characterisation to avoid 
redundancy. 
 
Fourier Transform Infrared Spectroscopy. FTIR spectra were recorded on a Bruker 
Vertex 70 spectrometer. Samples were prepared in deuterated phosphate buffer (pH=8) 
and placed between two CaF2 cells with 12mm diameter polytetrafluoroethylene (PTFE) 




Fluorescent microscope images were captured on the GE Cytell Imaging System using 
the Digital Imaging program. Samples were prepared on a standard glass slide and an 
18x18mm micro cover glass was placed on top.  Pictures were taken at 2000-2500 focus 
(micron). 
 
Doxorubicin encapsulation. Doxorubicin hydrochloride was solubilized in DMSO by 
sonication and 1 mM stock solution was made in PBS was made and subsequently diluted 
into the suspension of peptide micelles (final concentration of doxorubicin: 5 μM). The 
samples were then sonicated to allow doxorubicin diffusion into the hydrophobic core of 
the micelles. Fluorescence intensity of doxorubicin at 596 nm that corresponds to the 
maximum intensity (λex = 480 nm) was monitored over 96 h when incorporated into the 
2a peptide system with and without addition of MMP-9. A control experiment with free 
doxorubicin (doxorubicin in water, no peptide present) shows a low fluorescence 
intensity as previously reported (more intense fluorescence signal of doxorubicin is 
observed in hydrophobic environment compared to water- as fluorescence intensity 
changes with the polarity of the environment).1,2  
 
Fluorescence emission spectra were measured on a Jasco FP-6500 spectrofluorometer. 
Doxorubicin was excited at 480 nm and the emission intensity at 596 nm was monitored 







primer for CRISPR of human 





Primer for CRISPR of human 
MMP-9, Exon 1, 93% 
 
Quantification of circulating tumor cells. Circulating tumor cells were detected as 
described previously3,4, briefly 500 μL of blood was collected by cardiac puncture, snap 
frozen and kept at -70C. RNA was isolated using the Ambion Mouse RiboPureTM-Blood 
RNA Isolation Kit (AM1951, Applied Biosystems) and ~ 1 μg used for cDNA synthesis 
using SuperScriptTM kit (ThermoFisher Scientific, Life Technologies). Using qPCR 
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SYBR®Green (ThermoFisher Scientific) the levels of human GAPDH were quantified 
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